Effect of dose and combination of antihypertensives on interindividual blood pressure variability: A systematic review

Stroke

Volumn 42, Issue 10, 2011, Pages 2860-2865

  Webb, Alastair John Stewart ^a   Rothwell, Peter Malcolm ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

antihypertensive; blood pressure variability; combination; dose; stroke; systematic review

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE VARIABILITY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG MEGADOSE; FOLLOW UP; HUMAN; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZATION; REVIEW; STROKE; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION;

EID: 80053294699     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.110.611566     Document Type: Review

References (11)

1. Rothwell PM. Limitations of the usual BP hypothesis and importance of variability, instability, and episodic hypertension. Lancet. 2010;375: 938-948.
2. Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlof B, et al. Prognostic significance of visit-to-visit variability, maximum systolic BP, and episodic hypertension. Lancet. 2010;375:895-905.
3. Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JR, Dahlof B, Poulter NR, et al. ASCOT-BPLA and MRC Trial investigators. Effects of blockers and calcium-channel blockers on within-individual variability in BP and risk of stroke. Lancet Neurology. 2010;9:469-480.
4. Webb AJS, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive-drug class on interindividual variation in BP and risk of stroke: a systematic review and meta-analysis. Lancet. 2010;375: 906-915.
5. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology 2007 guidelines for the management of arterial hypertension. J Hypertens. 2007;25:1105-1187. (Pubitemid 46924065)
6. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11 000 participants from 42 trials. Am J Med. 2009;122:290-300.
7. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.
8. Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A; for the FEVER study group. The Felodipine Event Reduction (FEVER) study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens. 2005;23:2157-2172. (Pubitemid 41666745)
9. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001; 358:1033-1041.
10. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887-1898. (Pubitemid 351620109)
11. Bakris GL, Sarafidis PA, Weir MR, Dahlof B, Pitt B, Jamerson K, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk of cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet. 2010;375:1173-1181.